(Reuters) - Canada's Valeant Pharmaceuticals International Inc , embroiled in a bitter fight to take over Botox-maker Allergan Inc , posted a better-than-expected quarterly profit, helped by strong sales in all its markets.
Valeant posted a profit attributable to the company of $275.4 million, or 81 cents per share, in the third quarter ended Sept. 30, compared with a loss of $973.2 million, or $2.92 cents per share, a year earlier.
In the year-earlier quarter, the company took a restructuring charge of $305 million, primarily related to the acquisition of Bausch & Lomb, and an impairment charge of $645 million.
Cash earnings, or profit adjusted for one-time items, was $2.11 per share, above the average analyst estimate of $1.99 per share, according to Thomson Reuters I/B/E/S.
(Reporting by Rod Nickel in Winnipeg, Manitoba and Ashutosh Pandey in Bangalore; Editing by Saumyadeb Chakrabarty)
Relacionados
- KONICA MINOLTA firma Acuerdo Marco para Leasing Global con DLL para crear un negocio de cuenta global importante
- Álvarez de Miranda firma un acuerdo de fiscalización
- La firma se enfrenta de nuevo a la Audiencia Nacional
- PP acusa a la alcaldesa de "ocultar su declaración" sobre la firma falsa
- La Asamblea del FC Barcelona firma un récord de asistencia
